Physician profile
Mark Awad
NPI 1689244543
$1,770.67
in general payments reported to CMS, 2019-2025
20 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $268 · 2023: $561 · 2024: $590 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,502.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $236.35 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Emd Serono, INC. | $214.06 | 2023-2025 | Mavenclad |
| Abbvie INC. | $179.57 | 2023-2024 | Botox, Ubrelvy |
| Celgene Corporation | $126.49 | 2023 | Zeposia |
| Amylyx Pharmaceuticals, INC. | $121.22 | 2024 | Relyvrio |
| Biogen, INC. | $115.79 | 2022 | |
| Route 92 Medical, INC. | $112.03 | 2025 | |
| Imperative Care, INC | $106.13 | 2025 | Zoom 88-T Large Distal Platform |
| Genzyme Corporation | $99.02 | 2024 | |
| Ucb, INC. | $84.73 | 2023-2024 | Briviact |
| Astrazeneca Pharmaceuticals LP | $84.51 | 2022 | |
| Csl Behring | $82.19 | 2022-2023 | Idelvion |
| Depuy Synthes Sales INC. | $73.28 | 2025 | Cerebase |
| Avanir Pharmaceuticals, INC. | $27.60 | 2022 | |
| Pfizer INC. | $21.60 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $20.80 | 2023 | Keveyis |
| Bayer Healthcare Pharmaceuticals INC. | $20.55 | 2024 | |
| Microvention, INC. | $15.86 | 2025 | Web Aneurysm Embolization System |
| Livanova USA, INC. | $14.91 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Medtronic, INC. | $13.98 | 2023 | Axium Primetm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Awad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.